Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Smart contact lens could revolutionize glaucoma monitoring

NCT ID NCT06689696

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a new smart contact lens called miLens that records eye pressure patterns over 24 hours in 86 adults with glaucoma and healthy volunteers. Participants wore the lens in one eye and took smartphone readings every 15 minutes while awake. Researchers compared the lens data to standard office-based eye pressure measurements to see if the device is safe and reliable.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
miLens system (a soft contact lens with imaging and analysis software)
What this could lead to
If successful, this could lead to a convenient way to monitor eye pressure at home, helping doctors better manage glaucoma.
What could go wrong
This is a completed early-stage study with only 86 participants. The device may not be accurate enough or comfortable for long-term use, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

86 people

The number who actually took part.

Started

Feb 2025

Finished

Jan 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Subjects, aged between 22 and 80 years with: 1. primary open angle glaucoma (POAG) including normal tension glaucoma 2. status as POAG suspect including ocular hypertension (OHTN) 3. no prior diagnosis of POAG/POAG suspect (the subjects in (a) and (b) will henceforth be referred to as "POAG/OHTN" and subjects in (c) will be referred to as "healthy subjects")

Ages

22 to 80 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Subjects ≥22 to ≤80 years of age 2. Subjects with: * prior diagnosis of POAG in at least one eye, including normal tension glaucoma or prior diagnosis of POAG suspect including OHTN in at least one eye for whom no evidence or suspicion of structural or functional glaucomatous damage exists * Diagnosis of POAG from medical records characterized by open angles and (1) optic nerve cupping consistent with glaucoma, with diffuse or focal thinning of neuroretinal rim or nerve fiber layer defects or a difference in cup/disc ratio \> 0.2, not explained by anisometropia or other non-glaucomatous causes (2) visual field defects consistent with optic nerve cupping, with glaucomatous hemifield test outside normal limits or a pattern standard deviation (PSD) worse than 5th percentile (P\<0.05) by Standard Automated Perimetry, or VF defects with Goldmann visual field test consistent with glaucomatous nerve fiber layer loss including paracentral scotoma, nasal step or arcuate defects * Diagnosis of POAG suspect from medical records established by open angles and IOP ≥22 mmHg (OHTN) OR abnormal appearing optic disc appearance OR glaucomatous visual field defects * no prior history of POAG/OHTN in either eye 3. In subjects with no history of POAG/OHTN, GAT IOP difference between eyes must be ≤ 2 mmHg, with IOP no less than 10 mmHg in both eyes and no greater than 21 mmHg in both eyes. 4. Mean keratometry value is between 7.5 mm and 8.2 mm in at least one eye (the miLens eye) 5. GEN4 miLens contact lens fitting on the subject's eye is acceptable by a slit lamp exam at Day 0 (measurement study visit) 6. Subjects with ability to discontinue habitual IOP-lowering medications, if any, in both eyes on Day 0 visit until the end of the 24-hour wear period (and if applicable, similarly for the Week 1 visit) (No preservative-free topical glaucoma medications will be allowed for the duration of the study) 7. Able to understand, sign and complete the informed consent and available to complete the minimum set of self-acquired smartphone images over the 24-hour contact lens wear period, preferably at an assigned site and likely available for a repeat session after a week Exclusion Criteria: 1. BCVA worse than 20/200 in either eye 2. Greater than 6 diopters spherical equivalent in either eye 3. Greater than 3 diopters of keratometric cylinder in either eye 4. Central corneal thickness greater than 0.60 mm or less than 0.50 mm in either eye (per GAT study guidelines in ANSI Z80.10) 5. Known history of difficulty in obtaining Goldmann IOP measurements or any factors that might contribute to inaccurate Goldmann IOP measurements (e.g. lid squeezing or tremor) 6. Subjects who have had ocular surgery within the last 6 months in either eye 7. Subjects who have had corneal refractive surgery 8. History of Keratoconus, corneal scarring, or other chronic corneal disease in either eye 9. Subjects with contraindication for wearing contact lenses or history of intolerance or difficulties associated with contact lens use including history of dry eye disease 10. Subjects with current signs/symptoms of clinically significant dry eye disease 11. Active eye disease, injury or ocular abnormalities affecting the cornea, conjunctiva, or eyelids or slit lamp findings ≥ grade 3 12. Active inflammation of either eye 13. Active infection of either eye 14. Corneal vascularization of either eye 15. Known allergy to silicone 16. Known allergy to corneal anesthetic 17. Secondary forms of open angle glaucoma (OAG) in either eye 18. Poor or eccentric fixation in either eye 19. Nystagmus 20. Microphthalmos of either eye 21. Buphthalmos of either eye 22. Subject is pregnant, lactating or planning to become pregnant during the course of the study 23. Concurrent participation in any clinical trial 24. Disabling arthritis or limited motor coordination that might limit self-handling of a smart phone with miLens eyepiece attached. 25. Experience using or interacting with miLens and smartphone imaging app during a previous usability or clinical trial 26. Any affiliation with Smartlens and its employees 27. Subjects with any significant dermatologic condition (e.g., history of skin irritation, allergies, skin eczema) that poses a concern for skin contact with the camera eyepiece, based on the Investigator's judgment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Glaucoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • North Bay Eye Associates, Inc.

    Petaluma, California, 94954, United States

  • Nvision Clinical Reseacrh, LLC

    Fullerton, California, 92835, United States

  • Nvision Clinical Research, LLC

    Torrance, California, 90505, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.